1310875-99-0Relevant academic research and scientific papers
Notable difference in anti-HIV activity of integrase inhibitors as a consequence of geometric and enantiomeric configurations
Okello, Maurice,Mishra, Sanjay,Nishonov, Malik,Nair, Vasu
, p. 4112 - 4116 (2013)
While some examples are known of integrase inhibitors that exhibit potent anti-HIV activity, there are very few cases reported of integrase inhibitors that show significant differences in anti-HIV activity that result from distinctions in cis- and trans-c
Discovery of a potent HIV integrase inhibitor that leads to a prodrug with significant anti-HIV activity
Seo, Byung I.,Uchil, Vinod R.,Okello, Maurice,Mishra, Sanjay,Ma, Xiao-Hui,Nishonov, Malik,Shu, Qingning,Chi, Guochen,Nair, Vasu
supporting information; experimental part, p. 877 - 881 (2012/02/03)
Worldwide research efforts in drug discovery involving HIV integrase have produced only one compound, raltegravir, that has been approved for clinical use in HIV/AIDS. As resistance, toxicity, and drug-drug interactions are recurring issues with all class
PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS
-
, (2011/06/26)
New chiral and achiral oxy- substituted cyclopentyl pyridinone diketocarboxamides and their derivatives and methods for their preparations are disclosed. The compounds include tautomers, regioisomers and geometric isomers. These complex carboxamides are d
